If you'd invested in: AstraZeneca and Mitie Group
Pharmaceutical giant AstraZeneca is expected to grow its earnings, while outsourcer Mitie's share rice has been hit by a series of profit warnings.
How to profit as Britain piles on the pounds
The world is getting fatter – and with no easy solution to obesity in sight, investing in healthcare providers and food and drink makers could bring b…
Major setback for AstraZeneca
Pharma giant AstraZeneca was banking on a key clinical trial for its cancer drugs. It was a flop. What comes next? asks Alice Gråhns.
America's clampdown on tax inversions
The US government has issued new rules making it harder for American companies to cut their tax bill by relocating their headquarters.
A revolutionary new cancer treatment – and the blue-chip stock set to benefit
A new kind of cancer therapy could make a big difference to survival rates - and transform the fortunes of one big UK drugs company. Matthew Partridge…
The rise of ‘tax inversion’
More and more American businesses are snapping up companies in low-tax countries to make that their official home. British companies are in their sigh…